Thus, we postulate that joint activation of TGR5 and FXR would (1) provide more protection against NASH and associated dysmetabolic features and (2) limit the side effects observed by selective agonists. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.